Adjusted EBITDA guidance for fiscal 2024 has been raised to $17-19 million. The company is confident in FDA approval for EGRIFTA SV batch release in late October and managing inventory closely.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing